Quantitative FACS-based analysis confirmed the myeloid-cell-rich phenotype (Gr-1+/CD11b+ or CD11b+) of stably dedifferentiated syngeneic melanomas that also showed higher levels of Tnf and its downstream target Ccl2 as shown by ELISA assay of tissue lysates (Fig. 7f–h and Supplementary Fig. 9a). The gene discussed is CCL2; the disease is melanoma.